Petlife Pharmaceuticals, Inc. (PTLF)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Mar 3, 2026
1.00%
Market Cap 22.43K
Revenue (ttm) n/a
Net Income (ttm) -3.71M
Shares Out 222.12M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,100
Average Volume 269,176
Open 0.0001
Previous Close n/a
Day's Range 0.0001 - 0.0001
52-Week Range 0.0001 - 0.0010
Beta 69.86
RSI 47.26
Earnings Date n/a

About Petlife Pharmaceuticals

Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company’s principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. In addition, the company develops edible dog and cat treats. Petlife Ph... [Read more]

Sector Healthcare
CEO Sebastian Serrell-Watts
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol PTLF
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.